Chronic Plaque Psoriasis Market Report 2026

The chronic plaque psoriasis market size has grown strongly in recent years. It will grow from $22.26 billion in 2025 to $23.83 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to improved diagnosis of autoimmune skin disorders, wider availability of topical therapies, increased awareness of psoriasis management, expansion of dermatology clinics, improved access to specialty drugs.

The chronic plaque psoriasis market size is expected to see strong growth in the next few years. It will grow to $30.99 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing development of next-generation biologics, rising adoption of oral immunomodulators, expansion of precision dermatology approaches, growing focus on patient-centric treatment plans, increasing investment in autoimmune disease research. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted small molecule drugs, growing focus on personalized dermatology care, expansion of oral treatment options, enhanced emphasis on long-term disease control.

The rising incidence of immune system dysfunction is expected to drive the growth of the chronic plaque psoriasis market in the coming years. Immune system dysfunction occurs when the immune system does not function properly, increasing vulnerability to infections, autoimmune disorders, and cancers. The growing number of immune system dysfunction cases is linked to factors such as genetic predisposition, environmental influences, poor nutrition, chronic stress, and the increasing prevalence of autoimmune diseases and infections such as HIV. Treatment for chronic plaque psoriasis is necessary to regulate immune system dysfunction, as the immune system mistakenly causes excessive skin cell production, leading to inflammation and plaque formation. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 212,136 males and 362,137 females are projected to be living with rheumatoid arthritis in 2025, with these figures expected to increase by 2040 to around 280,040 males and 479,828 females. Therefore, the increasing incidence of immune system dysfunction is contributing to the growth of the chronic plaque psoriasis market.

Major companies operating in the chronic plaque psoriasis market are concentrating on the development of innovative therapies, including IL-17A and IL-17F inhibitors, to advance treatment options for chronic plaque psoriasis. IL-17A and IL-17F inhibitors are targeted biologic therapies that block interleukin-17A and interleukin-17F, pro-inflammatory cytokines that play a key role in immune responses, thereby reducing inflammation in autoimmune conditions such as chronic plaque psoriasis. For example, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bimekizumab is the first approved psoriasis treatment specifically designed to inhibit both interleukin-17A and interleukin-17F, two critical cytokines involved in inflammatory pathways. Its approval was supported by data from three Phase 3 multicenter trials, BE READY, BE VIVID, and BE SURE, which collectively evaluated its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

In October 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for an undisclosed amount. This acquisition strengthens Organon’s dermatology portfolio through the addition of VTAMA (tapinarof) Cream, 1%, an innovative dermatologic therapy. VTAMA Cream is a novel, nonbiologic, non-steroidal topical treatment approved by the U.S. Food and Drug Administration for the treatment of mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based company focused on the development and commercialization of innovative therapies within immunodermatology.

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol‑Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio‑Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic plaque psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic plaque psoriasis market by increasing costs of imported biologic drugs, specialty pharmaceutical ingredients, injection devices, and advanced manufacturing equipment. Healthcare systems in North America and Europe are most affected due to dependence on imported biologics, while Asia-Pacific faces cost pressures in drug production and export. These tariffs are contributing to higher treatment prices and reimbursement challenges. However, they are also driving domestic biologics manufacturing, regional pharmaceutical investments, and innovation in cost-efficient psoriasis therapies.

The chronic plaque psoriasis market research report is one of a series of new reports that provides chronic plaque psoriasis market statistics, including chronic plaque psoriasis industry global market size, regional shares, competitors with a chronic plaque psoriasis market share, detailed chronic plaque psoriasis market segments, market trends and opportunities, and any further data you may need to thrive in the chronic plaque psoriasis industry. This chronic plaque psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic plaque psoriasis is a long-lasting inflammatory skin disorder marked by the development of clearly defined, raised red lesions covered with silvery-white scales. These plaques most commonly affect areas such as the scalp, elbows, knees, and lower back, but they can appear on any part of the body. It is an autoimmune condition in which the immune system causes rapid skin cell turnover, resulting in the accumulation of cells on the skin’s surface.

The primary drug classes used for chronic plaque psoriasis include biologics and small-molecule drugs. Biologics are advanced therapies produced from living organisms that target specific components of the immune system to manage various diseases. These treatments are available in injectable, oral, and topical forms and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The chronic plaque psoriasis market consists of revenues earned by entities by providing services such as medication delivery services, customized treatment plans, and genetic and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic plaque psoriasis market also includes sales of vitamin D analogues, combination topicals, phosphodiesterase-4 inhibitors, and janus kinase inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.